Evidence map›Paper›PMID 40871046›Full record

ReviewPharmaceutics2025

Micro and Nano Drug Delivery Systems for the Treatment of Oral Mucositis: A Review.

Luciana Ângela Soares Maia, Tâmara Thaiane Almeida Siqueira, Carlos Alberto Arcelly Santos Bezerra, Jéssica Horana Pereira de Farias, Elquio Eleamen Oliveira

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Luciana Ângela Soares MaiaLaboratory of Synthesis and Drug Delivery, Paraiba State University, Rua Horácio Trajano de Oliveira, s/n, Cristo Redentor, João Pessoa 58075-540, PB, Brazil.
Tâmara Thaiane Almeida SiqueiraLaboratory of Synthesis and Drug Delivery, Paraiba State University, Rua Horácio Trajano de Oliveira, s/n, Cristo Redentor, João Pessoa 58075-540, PB, Brazil.
Carlos Alberto Arcelly Santos BezerraLaboratory of Synthesis and Drug Delivery, Paraiba State University, Rua Horácio Trajano de Oliveira, s/n, Cristo Redentor, João Pessoa 58075-540, PB, Brazil.ORCID 0009-0005-4562-0304
Jéssica Horana Pereira de FariasLaboratory of Synthesis and Drug Delivery, Paraiba State University, Rua Horácio Trajano de Oliveira, s/n, Cristo Redentor, João Pessoa 58075-540, PB, Brazil.
Elquio Eleamen OliveiraLaboratory of Synthesis and Drug Delivery, Paraiba State University, Rua Horácio Trajano de Oliveira, s/n, Cristo Redentor, João Pessoa 58075-540, PB, Brazil.ORCID 0000-0002-7214-4455

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 001Universidade Estadual da Paraíba 01/2025
6 · The paper itself

Abstract

Oral mucositis (OM) is a severe inflammatory condition of the oral mucosa that is commonly associated with cancer therapies. Traditional treatments typically have limited efficacy and significant side effects, necessitating alternative approaches. Nanobased drug delivery systems (DDSs) present promising solutions, enhancing therapeutic outcomes while minimizing side effects. This review aims to evaluate the use of nanobased DDSs to treat OM. To reach these aims, an extensive literature review was conducted using the following databases: BVS, PubMed, Scopus, and Web of Science. The search strategy included the keywords "microparticles," "nanoparticles," "drug delivery system," "oral mucositis," "therapy," and "treatment," combined with the Boolean operators "AND" and "OR." After applying filters for language, relevance, full-text availability, exclusion of review articles, and removal of duplicates, a total of 32 articles were selected for analysis. Of the 32 studies included in this review, 25 employed polymeric micro- or nanosystems for the treatment of OM. Regarding the stage of investigation, 10 studies were conducted in vitro, 16 were conducted in vivo, and 6 corresponded to clinical trials. Compared with conventional drug delivery approaches, most of these studies reported improved therapeutic outcomes. These findings highlight the potential of nanosystems as innovative strategies for enhancing OM treatment. Nonetheless, challenges in large-scale manufacturing, including reproducibility and safety, and the limited number of clinical trials warrant careful consideration. Future research with larger clinical trials is essential to validate these findings and effectively guide clinical practice.

Indexed as

dosage formdrug deliverymicrosystemsnanosystemsoral mucositistreatment

Identifiers

PMID40871046
PMCPMC12389656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.